...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Similar immunogenicity of measles-mumps-rubella (MMR) vaccine administrated at 8 months versus 12 months age in children
【24h】

Similar immunogenicity of measles-mumps-rubella (MMR) vaccine administrated at 8 months versus 12 months age in children

机译：儿童8个月和12个月大时接种的麻疹-腮腺炎-风疹（MMR）疫苗具有相似的免疫原性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Two doses of measles-mumps-rubella (MMR) strategy has been recommended by World Health Organization and is also widely adopted in many countries. In order to provide the evidence for perfecting the immunization strategy of MMR, this study evaluated the safety and immunogenicity of MMR with different two-dose schedule in infants. 280 participants were enrolled and randomly allocated to Group 1 (first dose at 8 months) or Group 2 (first dose at 12 months), and both groups administered the second dose at 10 months later. Solicited local and general symptoms after each vaccination with MMR were mild and infrequent in all participants of two groups. After administration of the first dose of MMR, seropositive rates were 100% in both groups for measles, 89.3% in Group 1 and 87.1% in Group 2 for mumps (P = 0.578), 92.0% in Group 1 and 92.9% in Group 2 (P = 0.393). The seropositive rates of mumps decreased significantly (from >86% to <65%) both in two groups (P < 0.001) 10 months after the first dose of MMR, but no significant change was found in measles and rubella. All children get the positive titer for three vaccines in two groups after given the second dose MMR, higher seroconversion rate was found for mumps both in two groups (71.7% vs 77.2%, P = 0.370). In conclusion, this study indicated that the MMR was well tolerated and immunogenic against measles, mumps and rubella with schedule of first dose both at 8 months and 12 months age. Our findings strongly supported that two doses of MMR can be introduced by replacing the first dose of MR in current EPI with MMR at 8 months age and the second dose at 18 months in China
机译：世界卫生组织已建议使用两剂麻疹-腮腺炎-风疹（MMR）策略，并且在许多国家也被广泛采用。为了为完善MMR的免疫策略提供证据，本研究评估了两种不同剂量的婴儿MMR的安全性和免疫原性。招募了280名参与者并将其随机分配到第1组（第8个月的第一剂）或第2组（第12个月的第一剂），并且两组均在10个月后给予第二剂。两组的所有参与者在每次接种MMR后的自发性局部和全身症状均较轻且很少见。服用第一剂MMR后，两组的麻疹血清阳性率分别为100％，第1组和第2组分别为89.3％和87.1％（P = 0.578），第1组为92.0％，第2组为92.9％ （P ＝ 0.393）。首次接种MMR后10个月，两组的腮腺炎血清阳性率均显着下降（从> 86％降至<65％）（P <0.001），但在麻疹和风疹中未发现明显变化。给予第二剂MMR后，所有儿童在两组中三种疫苗的滴度均呈阳性，两组腮腺炎的血清转化率更高（两组分别为71.7％和77.2％，P = 0.370）。总之，这项研究表明，MMR具有良好的耐受性，并且针对麻疹，腮腺炎和风疹具有免疫原性，并在8个月和12个月大时首次给药。我们的发现强烈支持可以通过在中国将8个月大的MMR替换为当前EPI中的第一剂MR，将18个月的第二剂MR替换为两种剂量的MMR

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号